Horien Biochemical Technology Co (ROCO:7814) EBIT: NT$8.05 Mil (TTM As of Dec. 2025)


ROCO:7814 Horien Biochemical Technology Co Ltd ROCO:7814
21 GF Score
Price NT$38.65
! 5 Warning Signs
View Full Analysis

What is Horien Biochemical Technology Co EBIT?

Horien Biochemical Technology Co ROCO:7814 -6.53% 21 EBIT is NT$8.05 Mil as of Dec. 2025. GuruFocus rates ROCO:7814 with a GF Score™ of 21/100. The stock has 5 warning signs investors should review.

Horien Biochemical Technology Co's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was NT$5.19 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$8.05 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Horien Biochemical Technology Co's annualized ROC % for the quarter that ended in Dec. 2025 was 18.94%. Horien Biochemical Technology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 27.01%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Horien Biochemical Technology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 0.60%.

Horien Biochemical Technology Co  (ROCO:7814) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Horien Biochemical Technology Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=16.712 * ( 1 - 0% )/( (88.399 + 88.107)/ 2 )
=16.712/88.253
=18.94 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=317.337 - 21.726 - ( 207.212 - max(0, 27.157 - 245.895+207.212))
=88.399

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=320.253 - 22.553 - ( 209.593 - max(0, 26.076 - 249.991+209.593))
=88.107

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Horien Biochemical Technology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=20.76/( ( (66.799 + max(9.38, 0)) + (65.814 + max(11.748, 0)) )/ 2 )
=20.76/( ( 76.179 + 77.562 )/ 2 )
=20.76/76.8705
=27.01 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(10.945 + 19.342 + 4.437) - (21.726 + 0 + 3.618)
=9.38

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(12.468 + 20.077 + 3.71) - (22.553 + 0 + 1.954)
=11.748

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Horien Biochemical Technology Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=8.05/1338.046
=0.60 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Horien Biochemical Technology Co EBIT Related Terms

Horien Biochemical Technology Co EBIT Historical Data

* Premium members only.

The historical data trend for Horien Biochemical Technology Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Horien Biochemical Technology Co EBIT Chart

Horien Biochemical Technology Co Annual Data
Trend Dec22 Dec23 Dec24 Dec25
EBIT
3.32 16.33 7.92 -4.97

Horien Biochemical Technology Co Quarterly Data
Dec22 Dec23 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial 13.38 7.42 0.00 2.86 5.19

ROCO:7814 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Horien Biochemical Technology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Horien Biochemical Technology Co EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Horien Biochemical Technology Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Horien Biochemical Technology Co's EV-to-EBIT falls into.


ROCO:7814
21GF Score
Horien Biochemical Technology Co Ltd ROCO:7814
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Horien Biochemical Technology Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$8.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$8.05 Mil mean?
Horien Biochemical Technology Co (ROCO:7814) has a EBIT of NT$8.05 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Horien Biochemical Technology Co.
Is Horien Biochemical Technology Co's EBIT too high?
Horien Biochemical Technology Co's current EBIT is NT$8.05 Mil. Overall, Horien Biochemical Technology Co has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Horien Biochemical Technology Co's EBIT compare to VRTX and REGN?
Horien Biochemical Technology Co's EBIT of NT$8.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Horien Biochemical Technology Co. Horien Biochemical Technology Co's current EBIT is NT$8.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Horien Biochemical Technology Co stock overvalued right now?
Horien Biochemical Technology Co (ROCO:7814) has a current EBIT of NT$8.05 Mil. The current EBIT is NT$8.05 Mil. Horien Biochemical Technology Co's overall GF Score™ is 21/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Horien Biochemical Technology Co (ROCO:7814), the current EBIT is NT$8.05 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Horien Biochemical Technology Co Business Description

Address Gongyecyu 38th Road, 7F-5 & 6, NO. 210, Situn District, Siehe Village, Taichung, TWN, 40768
Horien Biochemical Technology Co Ltd is engaged in the research and development of cosmetic raw materials and medical devices and facilities. The products of the company include Gen-Nusis, skin repairment ingredients, PeptioMax, the latest cosmetic raw material, Lifkin, and other substitutes used in dentistry and general surgery.
21GF Score

Get the complete analysis for ROCO:7814

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$38.65
Price